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dextroaortic arch.
③ Other anomalies detected in the fetal cardiovascular casts while
misdiagnosed in echocardiography: pulmonary artery crossover,
double outlet of the morphological left ventricle, abnormal origin of
the left common carotid artery by innominate artery, persistent left
superior vena cava, right atrial isomerism.
CONCLUSIONS ① Prenatal echocardiography has an indispensable
role in the diagnosis of pulmonary artery stenosis/atresia.
② Fetal cardiovascular cast can accurately and vividly represent the
orientation of great vessels and branches, which is helpful to understand
malformations of great vessels and to improve the diagnostic ability.
③ Pulmonary stenosis/atresia is always accompanied with other
cardiovascular abnormalities. More attention should be paid in the
analysis and diagnosis of associated malformations.
④ The comparative study of fetal echocardiography and cardio-
vascular cast on the diagnosis of pulmonary artery stenosis/atresia has
an important value in clinical application, which can offer valuable
information to the families and physicians, and also can evaluate
pregnancy outcome and provide appropriate guidance for further
necessary interventions.GW26-e2332
Acute pericarditis with pneumonia caused by Mycoplasma pneumonia in
childhood
Aihong Zeng,1 Yangying Ou,2 Muxue Yu,3 Mingming Guo,1 Xuan Dai,1
Hong Zhan1
1Department of Emergency, The First Afﬁliated Hospital of Sun Yat-Sen
University, Guangzhou, China; 2Department of Paediatrics,
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou,
China; 3Department of Paediatrics, The First Afﬁliated Hospital of Sun
Yat-Sen University, Guangzhou, China
OBJECTIVES Mycoplasma pneumoniae (M. pneumoniae) primarily
causes upper respiratory tract infection and atypical pneumonia in
school-aged children. Mycoplasma-associated Cardiac involvement
such as acute myocarditis, or pericarditis isan uncommon complica-
tion occurring in only less than 5% of patients. In this report, We
report one case with acute pericarditis due to M. pneumoniae in our
hospital over 5 year period.
METHODS Retrospective analysis was performed on 60 patients (<14
years old) with serologically conﬁrmed M. pneumoniae presenting to the
emergency department from January 2009 to March 2015. Among them,
one patient developed acute pericarditis due to M. pneumoniae infection.
RESULTS This 8 year old boy was admitted to the emergency
department in July 2009 with a 6 day history of fever up to 38.5C,
cough, wheeze, vomiting and lethargy. He had been started on oral
clarithromycin by pediatric clinic for one day.On the second hospital
day, the patient developed shortness of breath, obvious chest pain,
oliguria and the fever increased up to 39C. His rate of heart was up to
147bpm. Blood pressure was 76/51mmHg. the pericardial friction rub
could be heard at his precordium region and lung auscultation
revealed coarse rhonchi and wheezes. Blood test results showed His
hemoglobin levels at 11.0 g/dL; leukocyte count was 8700/mL; plate-
lets count was 215000/mL; aspartate aminotransferase was 132 IU/L;
alanine transaminase was 145 IU/L; creatinine kinase (CK) was 476 IU/
L; CK-MB was 124 ng/mL; pro-brain natriuretic peptide (pro-BNP) was
5218 pg/mL; lactate dehydrogenase level was 420 IU/L; erythrocyte
sedimentation rate was 14 mm/h; C-reactive protein was 19 mg/L; and
ELISA test forM. pneumoniae IgM was positive (1:800), inﬂuenza virus
(A and B), respiratory syncytial virus, adenovirus, parainﬂuenza virus,
Chlamydia pneumoniae, legionella pneumophila, Coxsackie A, Cox-
sackie B, and echovirus antibodies were negative. Abdominal hep-
atobiliary ultrasound was normal. Chest radiograph showed signs of
bronchopneumonia. Echocardiogram showed mild pericardial effu-
sion, normal left ventricle contractility. Based on these ﬁndings,
mycoplasma pneumonia complicated by acute pericarditis with peri-
cardial effusion were diagnosed. We treated the patient with intra-
venous azithromycin 10 mg/kg/day and intravenous immunoglobulin,
diuretics, dopamine, Antileukotriene agents, nebulized bronchodila-
tors and corticosteroid (ICS). on the next few days, the child’s symp-
toms of lower respiratory tract gradually improved and became
afebrile in four days, CK-MB and pro-BNP had gradually improved to
normal. Pericardial effusion had disappeared in two weeks.
CONCLUSIONS M. pneumoniae may be the pathogen of acute peri-
carditis patients. Appropriate and timely treatment is required.
Serological testing for Mycoplasma pneumoniae should be part of the
routine examination for pericarditis of unknown Origin.GW26-e4631
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review of the literature
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OBJECTIVES To describe a series of fetal ductus arteriosus constric-
tion and review the literatures.
METHODS The databases were searched for all cases of ductal
constriction detected during the last 3 years. The following variables
were analyzed: gestational age at diagnosis, indication for echocar-
diography, presence of right ventricular hypertrophy, presence of
tricuspid valve regurgitation, ductal pulsatility index, signs of fetal
heart failure, pregnancy and feto-neonatal outcome, and ductal status
at neonatal echocardiography.
RESULTS Six cases of fetus were presented with tricuspid valve
regurgitation secondary to an S-shaped ductus arteriosus with distal
constriction diagnosed by pulsed Doppler imaging. None of the cases
were secondary to maternal exposure to indomethacin or other non-
steroidal anti-inﬂammatory medications, or structural cardiac
lesions. A review of the recent English literature of similar cases is
presented.
CONCLUSIONS Constriction of the ductus arteriosus can be diag-
nosed prenatally with careful interrogation of the ductal arch using
pulsed Doppler sonography and complete fetal echocardiography.
Close monitoring of the fetus is then warranted to detect development
of right heart failure and to intervene prior to development of
hydrops.RELATED PHARMACEUTICAL CLINICAL RESEARCH
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OBJECTIVES Few studies have investigated the effects of angiotensin
blockades (ABs) on mortality and cardiovascular events of established
patients with atrial ﬁbrillation (AF). Aim of the current study was to
assess the association between ABs treatment and 1-year survival in
patients with AF in real-world clinical practice.
METHODS The present study consecutively enrolled AF patients
presenting to an emergency department at 20 hospitals in China from
November 1, 2008 to October, 31 2011. Multivariate Cox proportional
hazards regression was used on all the patients. End points of the
analyses were all-cause mortality, stroke and major adverse events
(MAE).
RESULTS A total of 2015 AF patients were included in the analysis,
and 42.2% patients received ABs treatment. During 1-year follow-up,
13.8% patients died. In the ﬁnal multivariate Cox proportional models
of predictors for all-cause mortality and stroke, after adjustment for
multiple relevant co-variables, ABs was signiﬁcantly associated with a
lower risk of all-cause mortality (HR: 0.66, 95% CI: 0.50-0.88,
p¼0.004) compared to non-ABs patients. Meanwhile, ABs was not an
independent risk factor for stroke (HR: 0.81, 95% CI: 0.56-1.19, p¼287).
CONCLUSIONS ABs usage was associated with a lower all-cause
mortality in patients with AF, as well as it did not increase the risk of
stroke and MAE incidences.
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OBJECTIVES To present the interim analysis of long-term safety and
effectiveness proﬁles of tadalaﬁl (Adcirca) in daily clinical practice
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arterial hypertension (PAH).
METHODS 818 case report forms from patients receiving tadalaﬁl
were collected from December 2009 (the drug launch time) to October
2013. The observation period was up to 2 years. 815 eligible patients
data was analyzed for safety and 765 PAH patients data was analyzed
for effectiveness. WHO functional classiﬁcation of PAH and 6-minute
walking test were used to evaluate effectiveness. The study was
conducted in accordance with the Good Post-marketing Study Practice
(GPSP) Ministerial Ordinance.
RESULTS The major patient characteristics were: median age (45.4
years), female (67.7%), and patient receiving tadalaﬁl for PAH treat-
ment (93.9%). 37.7% patients were with idiopathic PAH (IPAH), 2.0%
were familial PAH (FPAH), and 53.5% were associated with other
diseases (APAH) such as collagen vascular diseases (28.0%) and
congenital systemic-to-pulmonary shunts (23.9%). 31.17% of the pa-
tients developed drug-related treatment-emergent adverse events
(TEAEs) such as headache (8.83%), epistaxis (2.33%) and diarrhea
(2.21%), which is consistent with the existing safety proﬁle. As for
effectiveness, patients who improved more than 1 class of WHO
functional classiﬁcation (e.g. from Class II to Class I) were: 16.1% (120/
744) after 3 months treatment, 25.6% (73/285) after 12 months, and
32.4% (34/105) after 24 months. While patients who worsened over 1
class (e.g. from Class I to II) were: 1.5% (11/744) after 3 months, 1.4%
(4/285) after 12 month, and 4.8% (5/105) after 24 months. At the end of
observation (24 months since the administration), 6-minute walking
distance (6MWD) of 52 cases was increased by 51.7 m (mean distance
change, 95% CI, 23.0 – 80.4 m).
CONCLUSIONS The interim analysis of the All-Patient Investigation
suggests that no new safety concerns were identiﬁed in patients
receiving long-term tadalaﬁl treatment in daily clinical practice. Based
on the results of effectiveness analysis, in spite of limited numbers of
cases evaluated, improvement in effectiveness was noted in the
course of tadalaﬁl treatment.GW26-e5447
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OBJECTIVES In the current era of interventions, monitoring the
effectiveness of antiplatelet medications is vital. Considering the
emergence of antiplatelet resistance, reduced response to antiplatelet
therapy may leads to the stent thrombosis which is associated with
high morbidity and mortality. In the present study we evaluated the
effectiveness of thienopyridine-based antiplatelet regimens in post-
PCI patients using AggreGuide A-100 platelet aggregometer (Aggre-
dyne Inc., USA), a new, FDA-approved, easy-to-use, point-of-care
device developed to monitor platelet aggregation in whole blood us-
ing laser-light scattering technique.
METHODS In this prospective, single-center study, patients whore-
ceived antiplatelet therapy after undergoing coronary stent implan-
tation at an Indian tertiary care center during May-October, 2014 were
enrolled. Platelet aggregation was evaluated from the blood sample of
each study participant after 2–3 days of antiplatelet therapy using the
AggreGuideA-100. Test results were obtained as platelet activity index
(PAI), on a scale ranging from 0 to 10. Since the PAI value <2 is ob-
tained as no detectable aggregation during the test, such observations
were assigned the PAI value of 2. Test ﬁndings were interpreted as (a)
therapy working ifthe PAI value is 2–5 and (b) therapy not working if
the PAI value is above 5.
RESULTS A total of 220 patients (mean age: 55.359.51 years; 74.5%
males) were enrolled in the study. Among the study group, 79 (35.9%),
100 (45.5%), and 41 (18.6%) patients received Clopidogrel-, Prasugrel-,
and Ticagrelor based antiplatelet therapy respectively, at the discre-
tion of the treating physician. The AggreGuide A-100 testing indicated
that the effectiveness of antiplatelet therapy was inadequate in 43
(19.5%) patients. In particular, 30 (38.0%) patients receiving Clopi-
dogrel-, 11 (11.0%) patients receiving Prasugrel-, and 2 (4.9%) patients
receiving Ticagrelor- based antiplatelet therapy displayed inadequate
platelet response. Antiplatelet therapy was optimized accordingly for
these patients.
CONCLUSIONS Monitoring individual’s platelet activity should
become a new standard-of-care for patients on antiplatelet therapy.Using AggreGuide A-100, nearly 20% of patients were identiﬁed to
have inadequate response to thienopyridine-based antiplatelet ther-
apy in our study. Antiplatelet therapy was optimized accordingly for
these patients with inadequate response.
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OBJECTIVES Ticagrelor provides more consistent, rapid, and potent
platelet inhibition than clopidogrel, however, the interindividual
variability in response to ticagrelor was not absent. This study sought
to display the various distribution of ticagrelor antiplatelet respon-
siveness in Chinese acute coronary syndrome (ACS) patients.
METHODS Consecutive Chinese-Han patients with ACS who received
maintenance dose of ticagrelor (90 mg, bid) and aspirin (100 mg, qd)
were recruited from General Hospital of Chinese People’s Liberation
Army. After 5 days ticagrelor maintenance treatment, 5umol/L ADP
induced residue platelet aggregation (RPA) by light transmittance
aggregometry (LTA), and platelet inhibition (PIADP) measured by
thrombelastography (TEG) were measured.
RESULTS Overall, 532 ACS patients (Male: 72.56%, Age: 6011 years)
under ticagrelor maintenance treatment were recruited. Antiplatelet
responsiveness measured by LTA was available in 146 patients, and
by TEG in 176 patients. After 5 days’ ticagrelor maintenance dose
therapy, the value of RPA measured by LTA was (13.879.41)% on
average (range from 1.80% to 51%). With the pre-speciﬁc cutoffs for
HTPR (5umol/L ADP induced RPA >40%), 4 patients (2.74%) were
identiﬁed as HTPR. The value of PRA < 10% could be seen in ﬁfty-six
patients (38.36%). The value of PIADP measured by TEG was
(85.9217.79)% on average (ranged from 4.80% to 100%). The distri-
bution curve of both RPA and PIADP values moved to the direction of
strong antiplatelet responsiveness with the possibility of increased
risk for bleeding.
CONCLUSIONS The variability of ticagrelor antiplatelet responsive-
ness could be detected in Chinese ACS patients. Association of the
ticagrelor antiplatelet responsiveness variability to clinical efﬁcacy
and safety outcomes should be evaluated in the future.
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OBJECTIVES High on-treatment platelet reactivity (HTPR) after clo-
pidogrel therapy is accompanied by an increased risk of adverse
outcomes. Direct comparison between ticagrelor and high-dose clo-
pidogrel has not yet been reported in patients with acute myocardial
infarction (AMI) or coronary artery in-stent restenosis (ISR).
METHODS In a prospective, single-center, single-blind, randomized
trial, consecutive patients with AMI or coronary artery ISR treated
with standard-dose clopidogrel (75 mg/day) were screened with the
VerifyNow assay, deﬁning HTPR as P2Y12 reaction units (PRUs) >208.
Of the 102 screened patients, 48 (47.06%) patients with HTPR were
randomly assigned to either ticagrelor (180 mg/90 mg twice daily) or
high-dose clopidogrel (150 mg/day) for 24 hours.
RESULTS Baseline characteristics and mean PRUs were similar in both
groups. After 24 hours, ticagrelor was associated with a signiﬁcantly
lower platelet reactivity than high-dose clopidogrel (44.38  40.26 vs.
212.58  52.34 PRU, P<0.05). No patient receiving ticagrelor exhibited
HTPR, whereas 15 (62.50%) patients after treatment with high-dose
clopidogrel remained HTPR (P<0.05). During the follow-up (mean,
138.42 53.59 days), no patient exhibited a major bleeding event in
either treatment group.
CONCLUSIONS The prevalence of HTPR is high in patients with AMI
or coronary artery ISR after standard clopidogrel treatment. Ticagrelor
is signiﬁcantly more effective compared with high-dose clopidogrel in
overcoming HTPR.
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